EZH2 and head and neck squamous cell carcinoma: We also investigated whether squamocin could degrade other EZH2's non‐catalytic binding partners, such as p300[30] and RelA.[31] The results indicated that the accumulation of p300, but not RelA (p65), was reduced in two HNSCC cells treated with squamocin (Figure 4H).